Sonidegib Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 200 mg
Reference Brands: Odomzo (USA/EU)
Category:
Oncology Cancer Care
Sonidegib is available in Capsules
and strengths such as 200 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Sonidegib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Sonidegib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Sonidegib phosphate is an orally bioavailable, small-molecule Smoothened (SMO) antagonist with established antineoplastic activity. It is designed to selectively target and bind to the Smoothened (SMO) receptor, a key transmembrane protein involved in the hedgehog (Hh) signaling pathway. By inhibiting SMO, sonidegib phosphate effectively suppresses aberrant activation of the Hh pathway, which is known to play a critical role in tumor development and progression.
The hedgehog signaling pathway is essential for normal cellular growth, differentiation, and tissue repair during embryonic development and in certain adult tissues. However, abnormal and persistent activation of this pathway, often caused by mutations in the SMO receptor, can lead to uncontrolled cellular proliferation and cancer. Such dysregulation has been identified in multiple malignancies, particularly in basal cell carcinoma.
By blocking downstream signaling of the Hh pathway, sonidegib phosphate helps inhibit tumor cell growth and survival in cancers where this pathway is pathologically activated. Its oral administration provides a convenient therapeutic option for patients who are not suitable candidates for surgery or radiation therapy. Sonidegib phosphate represents a targeted treatment approach that addresses the molecular drivers of disease, making it a valuable option in modern oncology therapy portfolios.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing